(TSX-V:HOH), NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW CALGARY, Alberta, Nov. 28, 2025 (GLOBE NEWSWIRE) — High Arctic ‎Overseas Holdings Corp. (TSXV: HOH) (“High Arctic Overseas” or the “Corporation”) has released its third […]
(NYSE:ABBV), SKYRIZI(R) (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada's Drug Agency (CDA-AMC) for inflammatory bowel diseases, initially for Crohn's disease (CD) and now for ulcerative colitis (UC), supported by evidence from pivotal phase 3 clinical trials including MOTIVATE, ADVANCE, FORTIFY (for CD), and INSPIRE, COMMAND (for UC).1,2 AbbVie concludes letter
NEW YORK CITY, NY / ACCESS Newswire / November 28, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against WPP Plc ("WPP" or the "Company") (NYSE:WPP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged
NEW YORK CITY, NY / ACCESS Newswire / November 28, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ:SKYE) and certain officers.�� The class action, filed in the United States District Court for the Southern District of California, and docketed under 25-cv-03177,
NEW YORK CITY, NY / ACCESS Newswire / November 28, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed on behalf of Genius Group Limited ("Genius" or "the Company") (NYSE:GNUS) against Citadel Securities LLC ("Citadel") and Virtu Americas LLC ("Virtu") (together, the
NEW YORK CITY, NY / ACCESS Newswire / November 28, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against StubHub Holdings, Inc. ("StubHub" or "the Company") (NYSE:STUB) and certain of its officers. Class Definition This lawsuit seeks to recover damages against
SKYRIZI(R) (risankizumab) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance GlobeNewswire November 28, 2025 SKYRIZI(R) (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada's Drug Agency (CDA-AMC) for inflammatory bowel diseases, initially for Crohn's disease (CD) and now
High Arctic Overseas Announces 2025 Third Quarter Results GlobeNewswire November 28, 2025 NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW CALGARY, Alberta, Nov. 28, 2025 (GLOBE NEWSWIRE) — High Arctic ‎Overseas Holdings Corp. (TSXV:
CSE: URL / OTC: URLOF Record Quarterly Revenues and 135.0% Increase in Net Income NameSilo Technologies Corp. (CSE: URL) (PINKSHEETS: URLOF) (the “Company”), one of the largest domain registrars in the world, is pleased to announce the financial results for the quarter ending September30, 2025. The financial statements and related management's discussion and analysis (“MD&A”)
— FDA requests, and Vanda agrees to, a brief extension (to December 5, 2025) for the expedited re-review of the partial clinical hold on long-term studies — Separately, FDA recently issued labeling comments, and labeling discussions have formally begun for the New Drug Application of tradipitant for the prevention of vomiting induced by motion (PDUFA